Gerresheimer AG (ETR: GXI)

Germany flag Germany · Delayed Price · Currency is EUR
69.25
-0.90 (-1.28%)
Nov 21, 2024, 2:18 PM CET
-19.71%
Market Cap 2.42B
Revenue (ttm) 2.01B
Net Income (ttm) 114.30M
Shares Out 34.54M
EPS (ttm) 3.31
PE Ratio 21.20
Forward PE 12.86
Dividend 1.25 (1.78%)
Ex-Dividend Date Jun 6, 2024
Volume 94,501
Open 70.15
Previous Close 70.15
Day's Range 68.85 - 70.25
52-Week Range 68.85 - 111.20
Beta 0.94
Analysts n/a
Price Target n/a
Earnings Date Feb 26, 2025

About Gerresheimer AG

Gerresheimer AG, together with its subsidiaries, manufactures and sells medicine packaging, drug delivery devices, and solutions in Germany and internationally. It operates through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. The company offers prefillable syringes, plastic and glass packaging solutions, vials, glass cartridges and ampoules, bottles and containers, and glass bottles and jars, as well as caps, closures, applicators, and accessories; development, industrialization and contract manufactu... [Read more]

Sector Healthcare
Founded 1864
Employees 11,660
Stock Exchange Deutsche Börse Xetra
Ticker Symbol GXI
Full Company Profile

Financial Performance

In 2023, Gerresheimer AG's revenue was 1.99 billion, an increase of 9.54% compared to the previous year's 1.82 billion. Earnings were 116.13 million, an increase of 20.81%.

Financial Statements

News

EQS-DD: Gerresheimer AG: Dietmar Siemssen, buy

Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 13.11.2024 / 17:56 CET/CEST The issuer is solely responsi...

8 days ago - Wallstreet:Online

EQS-News: Solar power for Gerresheimer site in Momignies, Belgium

EQS-News: Gerresheimer AG / Key word(s): ESG Solar power for Gerresheimer site in Momignies, Belgium 14.10.2024 / 11:00 CET/CEST The issuer is solely responsible for the content of this announcement. ...

5 weeks ago - Wallstreet:Online

Gerresheimer AG (GRRMY) Q3 2024 Earnings Call Highlights: Navigating Growth Amid Challenges

Gerresheimer AG (GRRMY) Q3 2024 Earnings Call Highlights: Navigating Growth Amid Challenges

6 weeks ago - GuruFocus

Gerresheimer shares jump as activist investor buys over 5% stake

Gerresheimer's shares rose as much as 6.8% on Wednesday after a regulatory filing showed activist investor Ricky Chad Sandler had bought a 5.43% stake in German medical packaging maker.

6 weeks ago - Reuters

Gerresheimer AG Slashes Growth Forecast for 2024 and 2025

Gerresheimer AG revises its 2024 and 2025 growth forecasts due to slower market recovery and Hurricane Helene's impact on its US vial plant. Join their conference call on September 30, 2024, for more ...

7 weeks ago - Wallstreet:Online

EQS-Adhoc: Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025

EQS-Ad-hoc: Gerresheimer AG / Key word(s): Change in Forecast/Development of Sales Gerresheimer AG: Adjustment of growth guidance for 2024 and 2025 30-Sep-2024 / 16:21 CET/CEST Disclosure of an inside...

7 weeks ago - Wallstreet:Online

Stevanato Group, Gerresheimer and SCHOTT Pharma, Announce Strategic Industry “Alliance for RTU”

Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries, together w...

2 months ago - Wallstreet:Online

EQS-News: SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU”

EQS-News: SCHOTT Pharma AG & Co. KGaA / Key word(s): Agreement SCHOTT Pharma, Gerresheimer, and Stevanato Group announce strategic industry “Alliance for RTU” 26.09.2024 / 12:30 CET/CEST The issuer is...

2 months ago - Wallstreet:Online

EQS-News: Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU”

EQS-News: Gerresheimer AG / Key word(s): Alliance Gerresheimer, Stevanato Group and SCHOTT Pharma Announce Strategic Industry “Alliance for RTU” 26.09.2024 / 12:30 CET/CEST The issuer is solely respon...

2 months ago - Wallstreet:Online

Fill Finish Manufacturing Strategic Business Report 2023-2030 with Focus on 45+ Select Players Including Bausch+Strobel Maschinenfabrik Ilshofen, Becton, Dickinson and Co, & Gerresheimer Among Others – ResearchAndMarkets.com

DUBLIN — The “Fill Finish Manufacturing – Global Strategic Business Report” report has been added to ResearchAndMarkets.com’s offering. The global market for Fill Finish Manufacturing is estimated at ...

3 months ago - Financial Post

Gerresheimer AG (GRRMF) Q2 2024 Earnings Call Transcript

Gerresheimer AG (OTCPK:GRRMF) Q2 2024 Earnings Conference Call July 11, 2024 4:00 AM ET Company Participants Guido Pickert - IR Dietmar Siemssen - CEO Bernd Metzner - CFO Conference Call Participants ...

4 months ago - Seeking Alpha

Gerresheimer core profit meets forecast on weight-loss drug deals pipeline

Germany's Gerresheimer posted second-quarter adjusted core profit in line with market expectations on Thursday, driven by the deal pipeline for its plastics and devices segment, which supplies makers ...

4 months ago - Reuters

Gerresheimer supplies 'key players' in GLP-1 drugs market, CEO says

German packaging and medical equipment maker Gerresheimer is contracted to supply key players in the market for GLP-1 weight loss drugs, its CEO Dietmar Siemssen said on Thursday.

8 months ago - Reuters

Gerresheimer expects sales boost from burgeoning obesity drugs sector

German packaging and medical equipment maker Gerresheimer on Thursday posted adjusted first-quarter core profit in line with expectations of analysts polled by Vara Research, driven by the plastics an...

8 months ago - Reuters

Gerresheimer Makes Solid Start to the Financial Year 2024

Organic growth: Revenues +2.8%, adjusted EBITDA +5.9% Capacity expansion in the Americas, Europe and Asia progresses according to plan Guidance confirmed DUSSELDORF, GERMANY / ACCESSWIRE / April 11, 2...

8 months ago - Accesswire

Gerresheimer CEO dubs weight-loss drugs a meaningful positive catalyst

Dietmar Siemssen – the chief executive of Gerresheimer AG (ETR: GXI) expects strong demand for weight-loss drugs to be a meaningful tailwind for his company. Weight-loss drugs to boost $GXI revenue gr...

8 months ago - Invezz

Weight-loss drug deals to drive around 4% of Gerresheimer yearly growth, CEO says

Gerresheimer CEO Dietmar Siemssen said he expects about 4% of the company's revenue growth per year from deals to supply makers of drugs for weight loss and diabetes with vials, cartridges, syringes a...

8 months ago - Reuters

Gerresheimer AG (GRRMF) Q4 2023 Earnings Call Transcript

Gerresheimer AG (GRRMF) Q4 2023 Earnings Call Transcript

9 months ago - Seeking Alpha

Gerresheimer Decisively Continues on Profitable Growth Course in Financial Year 2023

Organic revenue growth in 2023: +10.4% Organic adjusted EBITDA growth in 2023: +17.5% Favorable product mix boosts profitability High order backlog and global capacity expansion secure profitable grow...

9 months ago - Accesswire

Gerresheimer awarded EcoVadis Gold status again

-  Gerresheimer among the top 5% of assessed businesses -  Total score increases to 72/100 points -  Status demonstrates consistent implementation of CSR strategy DUESSELDORF, Germany , Oct. 18, 2023 ...

1 year ago - PRNewsWire

Gerresheimer AG (GRRMF) Q3 2023 Earnings Call Transcript

Gerresheimer AG (OTCPK:GRRMF) Q3 2023 Earnings Conference Call October 5, 2023 4:00 AM ET Company Participants Bernhard Wolf - Corporate Senior Director, Investor Relations Dietmar Siemssen - Chief Ex...

1 year ago - Seeking Alpha

Gerresheimer AG: Gerresheimer on Track to Another Strong Financial Year

Organic revenue growth of 12.6% in the first nine months of the financial year 2023 Adjusted EBITDA up organically by 20.6% Order intake at record high: new orders for syringes and pens for GLP-1 drug...

1 year ago - Accesswire

Gerresheimer AG: Gerresheimer Continues Dynamic Growth in First Half of 2023

Organic revenue growth of 16.6% in first half of 2023 Adjusted EBITDA up 23.0% organically Production capacities expanded in Europe, the United States, and Mexico Guidance for full year 2023 confirmed...

1 year ago - Accesswire

Gerresheimer AG (GRRMF) Q1 2023 Earnings Call Transcript

Gerresheimer AG (OTCPK:GRRMF) Q1 2023 Earnings Conference Call April 6, 2023 4:00 AM ET Company Participants Carolin Nadilo - Head of Investor Relations Dietmar Siemssen - Chief Executive Officer Dr. ...

1 year ago - Seeking Alpha

Gerresheimer AG (GRRMF) Q4 2022 Earnings Call Transcript

Gerresheimer AG (OTCPK:GRRMF) Q4 2022 Results Conference Call February 23, 2023 4:00 AM ET Company Participants Carolin Nadilo - Head of Investor Relations Dietmar Siemssen - Chief Executive Officer D...

1 year ago - Seeking Alpha